Tertiary Nav - Press Releases Press ReleasesMedia Statements Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Date Title 11/3/21 Sarepta Therapeutics Announces Third Quarter 2021 Financial Results and Recent Corporate Developments 11/2/21 Sarepta Therapeutics to Present at Upcoming Investor Conferences 10/29/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 10/27/21 Sarepta Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Developments on November 3, 2021 10/13/21 Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock 10/12/21 Sarepta Therapeutics Announces Preliminary Financial Results for the Third Quarter Ended September 30, 2021 10/12/21 Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock 10/11/21 Sarepta Therapeutics’ SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne 10/4/21 Sarepta Therapeutics Opens Genetic Therapies Center of Excellence in Columbus, Ohio 10/4/21 Sarepta Therapeutics Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001, a Gene Therapy for the Treatment of Duchenne Muscular Dystrophy Pagination First page « first Previous page ‹ previous … Page 8 Page 9 Page 10 Page 11 Current page 12 Page 13 Page 14 Page 15 Page 16 … Next page next › Last page last » Displaying 111 - 120 of 813 Toolkit Print Page | Email Alerts | RSS Feeds | Contacts
Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Date Title 11/3/21 Sarepta Therapeutics Announces Third Quarter 2021 Financial Results and Recent Corporate Developments 11/2/21 Sarepta Therapeutics to Present at Upcoming Investor Conferences 10/29/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 10/27/21 Sarepta Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Developments on November 3, 2021 10/13/21 Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock 10/12/21 Sarepta Therapeutics Announces Preliminary Financial Results for the Third Quarter Ended September 30, 2021 10/12/21 Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock 10/11/21 Sarepta Therapeutics’ SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne 10/4/21 Sarepta Therapeutics Opens Genetic Therapies Center of Excellence in Columbus, Ohio 10/4/21 Sarepta Therapeutics Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001, a Gene Therapy for the Treatment of Duchenne Muscular Dystrophy Pagination First page « first Previous page ‹ previous … Page 8 Page 9 Page 10 Page 11 Current page 12 Page 13 Page 14 Page 15 Page 16 … Next page next › Last page last » Displaying 111 - 120 of 813